Global COPD Drugs Market: Analysis By Drug Type (Combination Therapy, Anticholinergics, Beta-Agonist, Inhaled Corticosteroids, Others), Pipeline Drugs, By Region, By Country (2019 Edition)- Forecast to 2023

Limited Time Offer

Executive Summary

A comprehensive research report created through extensive primary research (inputs from industry experts, companies, stakeholders) and secondary research, the report aims to present the analysis of COPD Drugs Market. The report analyses the COPD Drugs Market By Drug Type (Combination Therapy Drugs, Anticholinergics, Beta-Agonist, Inhaled Corticosteroids, and Others). The report analyses the COPD Drugs Market, By Region (North America, Europe, Asia Pacific, Rest of the World) and By Country (U.S., Canada, Germany, U.K, France, Italy, China, Japan, India) for the historical period of 2013-2017 and the forecast period of 2018-2023. This report also includes pipeline analysis for few COPD drugs.

According to Azoth Analytics research report ?Global COPD Drugs Market: Analysis By Drug Type (Combination Therapy Drugs,  Anticholinergics,  Beta-Agonist, Inhaled Corticosteroids, Others), Pipeline Drugs, By Region, By Country (2019 Edition): Forecast to 2023 - By Region (North America, Europe, APAC, ROW), By Country (U.S., Canada, Germany, U.K, France, Italy, China, Japan, India)?, the COPD drugs market is projected to display robust growth represented by a CAGR of 2.47% during 2018 ? 2023.

Over the recent years, COPD Drugs market has been witnessing growth on account of several driving factors including growing prevalence of COPD associated diseases, rising patient population, and increase in availability of novel combination therapy drugs. Moreover, increasing awareness regarding COPD, high smoking prevalence, rising pollution level, growing medical spending, favorable government initiatives, public private partnership have been driving the market growth. In addition, rising geriatric population, increasing global healthcare expenditure and technological advancements in pharmaceuticals research, and growing scope in middle and low income countries with large patient population is anticipated to impel the market growth of the COPD drugs market. However, growing portfolio of generic COPD drugs, and patent expiration of few innovator drugs in upcoming years are expected to hinder the market performance during forecasted period.

In this research report, the market is segmented on the basis of drug type. By drug type, the combination therapy COPD drugs are predicted to hold their dominant position in the market, especially LABA/LAMA and triple combination ICS/LABA/LAMA market is expected to gain more traction in forecasted period. Amongst the regions, North America accounts for the largest regional share in the global COPD drugs market in 2017. The largest share of North America is attributed to presence of enormous number of patient base and more emphasis towards prescribed branded drugs.

The report titled ?Global COPD Drugs Market: Analysis By Drug Type (Combination Therapy Drugs,  Anticholinergics,  Beta-Agonist, Inhaled Corticosteroids, Others), Pipeline Drugs, By Region, By Country (2019 Edition): Forecast to 2023 - By Region (North America, Europe, APAC, ROW), By Country (U.S., Canada, Germany, U.K, France, Italy, China, Japan, India? has covered and analysed the potential of COPD drugs market and provides statistics and information on market size, shares and growth factors. The report intends to provide cutting-edge market intelligence and help decision makers take sound investment evaluation. Besides, the report also identifies and analyses the emerging trends along with major drivers, challenges and opportunities in the COPD drugs market. Additionally, the report also highlights market entry strategies for various companies across the globe along with pipeline and product analysis. 
Scope of the Report

Global COPD Drugs Market (Actual Period: 2013-2017, Forecast Period: 2018-2023)
? COPD Drugs Market? Size, Growth, Forecast
? Analysis By Drug Type - Combination Therapy COPD Drugs, Anticholinergics COPD Drugs, Beta-Agonist COPD Drugs, Inhaled Corticosteroids COPD Drugs, and Other COPD Drugs.

Regional COPD Drugs Market ? North America, Europe, Asia Pacific, Rest of the World (Actual Period: 2013-2017, Forecast Period: 2018-2023)
? COPD Drugs Market? Size, Growth, Forecast
? Analysis By Drug Type - Combination Therapy COPD Drugs, Anticholinergics COPD Drugs, Beta-Agonist COPD Drugs, Inhaled Corticosteroids COPD Drugs, and Other COPD Drugs.

Country Analysis ? U.S., Canada, Germany, U.K, France, Italy, China, Japan, India (Actual Period: 2013-2017, Forecast Period: 2018-2023)
? COPD Drugs Market? Size, Growth, Forecast
? Analysis By Drug Type - Combination Therapy COPD Drugs, Anticholinergics COPD Drugs, Beta-Agonist COPD Drugs, Inhaled Corticosteroids COPD Drugs, Other COPD Drugs.

Other Report Highlights
? Pipeline Analysis- PT010, Duaklir, Nemiralisib, Danirixin.
? Product Analysis.
? Market Dynamics ? Drivers and Restraints.
? Market Trends.
? Porter Five Forces Analysis.
? SWOT Analysis.
? Company Analysis - Glaxo SmithKline, AstraZeneca, Boehringer-Ingelheim, TEVA Pharmaceuticals, Chiesi Pharmaceuticals, Novartis, Merck, Cipla, Mylan, Vectura, Sunovion

Customization of the Report
The report could be customized according to the client?s specific research requirements. No additional cost will be required to pay for limited additional research.
Table of Contents

1. Research Methodology

2. Executive Summary

3. Strategic Recommendation
3.1 Invest in COPD Generic Drugs
3.2 Asia Pacific Region To Witness The Fastest Growth

4. COPD Drugs Products Outlook

5. Global COPD Drugs Market: Growth and Forecast
5.1 By Value (2013-2017)
5.2 By Value (2018-2023)

6. Global COPD Drugs Market: Segmental Analysis
6.1 Global COPD Drugs Market Size, By Drug Type: Breakdown (%)
6.1.1 Global COPD Drugs Market Size, By Drug Type, 2017 (%)
6.1.2 Global COPD Drugs Market Size, By Drug Type, 2023 (%)
6.2 Global Combination Therapy COPD Drugs Market  Size, By Value (2013-2023)
6.3 Global Anticholinergics COPD Drugs Market Size, By Value (2013-2023)
6.4 Global Beta- Agonist COPD Drugs Market Size, By Value (2013-2023)
6.5 Global ICS COPD Drugs Market Size, By Value (2013-2023)
6.6 Global Other COPD Drugs Market Size, By Value (2013-2023)
6.6 Global COPD Drugs: Market Attractiveness, By Drug Type

7. Global COPD Drugs Market: Regional Analysis
7.1 Global COPD Drugs Market Size, By Region : Breakdown (%)
7.1.1 Global COPD Drugs Market Size, By Region, 2017 (%)
7.1.2 Global COPD Drugs Market Size, By Region, 2023 (%)

8. North America COPD Drugs Market: Growth and Forecast
8.1 North America COPD Drugs Market: Segmental Analysis
8.2 North America COPD Drugs Market Size, By Drug Type: Breakdown (%)
8.2.1 North America COPD Drugs Market Size, By Drug Type, 2017 (%)
8.2.2 North America COPD Drugs Market Size, By Drug Type, 2023 (%)
8.3 North America Combination Therapy COPD Drugs Market  Size, By Value (2013-2023)
8.4 North America  Anticholinergics COPD Drugs Market Size, By Value (2013-2023)
8.5 North America Beta- Agonist COPD Drugs Market Size, By Value (2013-2023)
8.6 North America ICS COPD Drugs Market Size, By Value (2013-2023)
8.7 North America Other COPD Drugs Market Size, By Value (2013-2023)
8.9 North America COPD Drugs Market: Country Analysis (U.S and Canada)
8.9.1 U.S COPD Drugs Market, By Value (2013-2023)
8.9.2 U.S COPD Drugs Market, By Drug Type, By Value (2013-2023)
8.9.3 Canada COPD Drugs Market, By Value (2013-2023)
8.9.4 Canada COPD Drugs Market, By Drug Type, By Value (2013-2023)

9. Europe COPD Drugs Market: Growth and Forecast
9.1 Europe COPD Drugs Market: Segmental Analysis
9.2 Europe COPD Drugs Market Size, By Drug Type: Breakdown (%)
9.1.2 Europe COPD Drugs Market Size, By Drug Type, 2017 (%)
9.1.3 Europe COPD Drugs Market Size, By Drug Type, 2023 (%)
9.3 Europe Combination Therapy COPD Drugs Market  Size, By Value (2013-2023)
9.4 Europe America  Anticholinergics COPD Drugs Market Size, By Value (2013-2023)
9.5 Europe America Beta- Agonist COPD Drugs Market Size, By Value (2013-2023)
9.6 Europe America ICS COPD Drugs Market Size, By Value (2013-2023)
9.7 Europe America Other COPD Drugs Market Size, By Value (2013-2023)
9.8 Europe COPD Drugs Market: Country Analysis (Germany, France, U.K, Italy)
9.8.1 Germany COPD Drugs Market, By Value (2013-2023)
9.8.2 Germany COPD Drugs Market, By Drug Type, By Value (2013-2023)
9.8.4 France COPD Drugs Market, By Value (2013-2023)
9.8.5 France COPD Drugs Market, By Drug Type, By Value (2013-2023)
9.8.7 UK COPD Drugs Market, By Value (2013-2023)
9.8.6 UK COPD Drugs Market, By Drug Type, By Value (2013-2023)
9.8.7 Italy COPD Drugs Market, By Value (2013-2023)
9.8.8 Italy COPD Drugs Market, By Drug Type, By Value (2013-2023)

10. APAC COPD Drugs Market: Growth and Forecast
10.1 APAC COPD Drugs Market: Segmental Analysis
10.2 APAC COPD Drugs Market Size, By Drug Type: Breakdown (%)
10.2.1 APAC COPD Drugs Market Size, By Drug Type, 2017 (%)
10.2.2 APAC COPD Drugs Market Size, By Drug Type, 2023 (%)
10.3 APAC Combination Therapy COPD Drugs Market  Size, By Value (2013-2023)
10.4 APAC Anticholinergics COPD Drugs Market Size, By Value (2013-2023)
10.5 APAC Beta- Agonist COPD Drugs Market Size, By Value (2013-2023)
10.6 APAC ICS COPD Drugs Market Size, By Value (2013-2023)
10.7 APAC Other COPD Drugs Market Size, By Value (2013-2023)
10.8 APAC COPD Drugs Market: Country Analysis (China, Japan, and India)
10.8.1 China COPD Drugs Market, By Value (2013-2023)
10.8.2 China COPD Drugs Market, By Drug Type, By Value (2013-2023)
10.8.3 Japan COPD Drugs Market, By Value (2013-2023)
10.8.4 Japan COPD Drugs Market, By Drug Type, By Value (2013-2023)
10.8.5 India COPD Drugs Market, By Value (2013-2023)
10.8.6 India COPD Drugs Market, By Drug Type, By Value (2013-2023)

11. ROW COPD Drugs Market: Growth and Forecast
11.1 ROW COPD Drugs Market: Segmental Analysis
11.2 ROW COPD Drugs Market Size, By Drug Type: Breakdown (%)
11.1.1 ROW COPD Drugs Market Size, By Drug Type, 2017 (%)
11.1.2 ROW COPD Drugs Market Size, By Drug Type, 2023 (%)
11.3 ROW Combination Therapy COPD Drugs Market  Size, By Value (2013-2023)
11.4 ROW Anticholinergics COPD Drugs Market Size, By Value (2013-2023)
11.5 ROW Beta- Agonist COPD Drugs Market Size, By Value (2013-2023)
11.6 ROW ICS COPD Drugs Market Size, By Value (2013-2023)
11.7 ROW Other COPD Drugs Market Size, By Value (2013-2023)

12. Global COPD Drugs Market: Pipeline Analysis

13. Global COPD Drugs Market: Market Dynamics
13.1 Global COPD Drugs Market: Drivers
13.2 Global COPD Drugs Market: Restrains
13.3 Global COPD Drugs Market: Trends
13.4 Global COPD Drugs Market: Product Benchmarking
13.5 Global COPD Drugs Market: Sales Analysis, By Company

14. Porter Five Force Analysis

15. SWOT Analysis

16. Company Profiles
16.1 GSK 
16.2 AstraZeneca 
16.3 Boehringer-Ingelheim
16.4 Teva Pharmaceuticals 
16.5 Chiesi Farmaceutici S.p.A.
16.6 Novartis 
16.7 Cipla 
16.8 Mylan 
16.9 Vectura Group Plc,
16.10 Sunovion

List of Figures Figure 1: Management of COPD Figure 2: Global COPD Drugs Market Size, By Value, 2013-2017 (USD Million) Figure 3: Smoking Prevalence Among Adults, By Gender, 2015 Figure 4: Cigarette Sales Share, By Region, 2017 (% of total) Figure 5: Deaths Due To Air Pollution, By Disease Type, 2016 Figure 6: Percentage of NCD Cases Due to Air Pollution, 2016 Figure 7: Global PM2.5 air pollution, mean annual exposure, 2012-2016 Figure 8: Global Aged Population(Above 65), By Country, 2017 (% of total) Figure 9: Global Aged Population (Above 65), 2013-2017 (% of total) Figure 10: Global Overweight Population (Age above 18), 2013-2016 (% of total) Figure 11: Global Overweight Population (Age above 18), By Sex, 2016 (% of total) Figure 12: COPD Facts and Figures Figure 13: Generic Market Value Share, In 2006 (Left) &2016 (Right), By Region Figure 14: Healthcare Expenditure (Share of GDP), By Selected Country, 2013-2017 (In %) Figure 15: Expected Global Medical Spending in 2020, By Product Type, (% of Total) Figure 16: Expected Global Medical Spending in 2020, By Region, (% of Total) Figure 17: COPD DAYLs Per 100000, By Country, All Sex, All Age,2017 Figure 18: GDP Per Capita PPP, By Region, 2018 (in Thousand USD) Figure 19: Global Expected Healthcare Industry Outlook Figure 20: Regional Expected Healthcare Industry Growth Rate By Year 2020 Figure 21: Regional Expected Healthcare Industry Growth Rate By Year 2020 Figure 22: Global COPD Drugs Market Size, By Drug Type, 2017 (%) Figure 23: Global COPD Drugs Market Size, By Drug Type, 2023F (%) Figure 24: Global Combination Therapy COPD Drugs Market, By Value, 2013-2017 (USD Million) Figure 25: Global Combination Therapy COPD Drugs Market, By Value, 2018-2023(USD Million) Figure 26: Global Anticholinergics COPD Drugs Market, By Value, 2013-2017 (USD Million) Figure 27: Global Anticholinergics COPD Drugs Market, 2018-2023(USD Million) Figure 28: Global Beta-Agonist COPD Drugs Market, By Value, 2013-2017 (USD Million) Figure 29: Global Beta-Agonist COPD Drugs Market, By Value, 2018-2023(USD Million) Figure 30: Global ICS COPD Drugs Market, By Value, 2013-2017 (USD Million) Figure 31: Global ICS COPD Drugs Market, By Value, 2018-2023(USD Million) Figure 32: Global Other COPD Drugs Market, By Value, 2013-2017 (USD Million) Figure 33: Global Other COPD Drugs Market, By Value, 2018-2023(USD Million) Figure 34: Global Market Attractiveness, By Product Type, 2023F Figure 35: Global COPD Drugs Market Size, By Region, 2017 (%) Figure 36: Global COPD Drugs Market Size, By Region, 2023F (%) Figure 37: North America COPD Drugs Market, By Value, 2013-2017 (USD Million) Figure 38: United States Spending on Medicines, 2013-2017 (In USD Billion) Figure 39: Patented and Non-Patented Drugs Sales in Canada, 2013-2016 (USD Billion) Figure 40: North America, Smoking Prevalence, Age 15+, 2013-2016 Figure 41: North America, Smoking Prevalence, Age 15+, 2013-2016 Figure 42: United States health care expenditure per capita,2013-2016(USD) Figure 43: Canada health care expenditure per capita,2013-2016(USD) Figure 44: North America population aged 65 and above, 2013-2017 (% of total) Figure 45: North America Healthcare Cost Per Capita, 2017 (USD) Figure 46: North America GDP per Capita, 2013-2017 (USD) Figure 47: North America COPD Drugs Market, By Value, 2018-2023 (USD Million) Figure 48: North America COPD Drugs Market Size, By Drug Type, 2017 (%) Figure 49: North America COPD Drugs Market Size, By Drug Type, 2023F (%) Figure 50: North America COPD Drugs Market, By Drug Type, By Value, 2013-2017 (USD Million) Figure 51: North America COPD Drugs Market, By Drug Type , By Value, 2018-2023(USD Million) Figure 52: North America COPD Drugs Market Size, By Countries, 2017 (%) Figure 53: North America COPD Drugs Market Size, By Countries, 2023F (%) Figure 54: USA COPD Drugs Market, By Value, 2013-2017 (USD Million) Figure 55: USA COPD Drugs Market, By Value, 2018-2023(USD Million) Figure 56: Smoking Prevalence, Age 15+, 2012-2016 Figure 57: Canada, PM2.5 air pollution, mean annual exposure (micrograms per cubic meter), 2012-2016 Figure 58: United States Per Capita Spending on Medicines, 2013-2017 (In USD) Figure 59: Pharmacy & Drug Store Sales in United States, 2013-2016 (In USD Billion) Figure 60: Medical and Healthcare Research & Development Spending, 2013-2016 (In USD Million) Figure 61: U.S., Population ages 65 and above, 2013-2017 (% of total) Figure 62: U.S., Population ages 65 and above, Forecast (In Millions) Figure 63: U.S., Per Capita Expenditure on Healthcare, 2012-2018E (In USD) Figure 64: U.S., GDP (Current USD), 2013-2017 (In USD Trillion) Figure 65: USA COPD Drugs Market Size, By Drug Type, 2017 (%) Figure 66: USA COPD Drugs Market Size, By Drug Type, 2023F (%) Figure 67: USA COPD Drugs Market, By Drug Type, By Value, 2013-2017 (USD Million) Figure 68: USA COPD Drugs Market, By Drug Type, By Value, 2018-2023(USD Million) Figure 69: Canada COPD Drugs Market, By Value, 2013-2017 (USD Million) Figure 70: Canada COPD Drugs Market, By Value, 2018-2023(USD Million) Figure 71: Percentage Change in Deaths Between, 2007?2017 Due to Respiratory Diseases Figure 72: Canada, PM2.5 air pollution, mean annual exposure (micrograms per cubic meter), 2012-2016 Figure 73: Canada, Smoking Prevalence, Age 15+, 2012-2016 Figure 74: Number of Retail Pharmacies in Canada, 2013-2017 Figure 75: Number of Hospitals Establishments in Canada, By Province, 2015 Figure 76: Canada, Expenditure on Health as a share of GDP, 2012-2017 (in %) Figure 77: Canada, Per Capita Healthcare Expenditure, 2012-2017 (USD) Figure 78: Canada, Population ages 65 and above, 2012-2017 (% of total) Figure 79: Canada COPD Drugs Market Size, By Drug Type, 2017 (%) Figure 80: Canada COPD Drugs Market Size, By Drug Type, 2023F (%) Figure 81: Canada COPD Drugs Market, By Drug Type, By Value, 2013-2017 (USD Million) Figure 82: Europe COPD Drugs Market, By Value, 2013-2017 (USD Million) Figure 83: Europe Health Expenditure, By Select Country, 2016 (% of GDP) Figure 84: Europe Population ages 65 years and above (% of total population), 2013-17 Figure 85: European Union, PM2.5 air pollution, mean annual exposure (micrograms per cubic meter), 2012-2016 Figure 86: European Union, Smoking Prevalence, Age 15+, 2012-2016 Figure 87: Cause of Death, EU-28, 2015, Per 1000000 inhabitants, Both Sex Figure 88: Europe, COPD Prevalence, By Selected Countries, 2017, (In Million) Figure 89: Mean Average Age At Which Majority of Population Affected By COPD, By Region Figure 90: Europe COPD Drugs Market, By Value, 2018-2023 (USD Million) Figure 91: Europe COPD Drugs Market Size, By Drug Type, 2017 (%) Figure 92: Europe COPD Drugs Market Size, By Drug Type, 2023F (%) Figure 93: Europe COPD Drugs Market, By Drug Type, By Value, 2013-2017 (USD Million) Figure 94: Europe COPD Drugs Market Size, By Countries, 2017 (%) Figure 95: Europe COPD Drugs Market Size, By Countries, 2023F (%) Figure 96: Germany COPD Drugs Market, By Value, 2013-2017 (USD Million) Figure 97: Germany COPD Drugs Market, By Value, 2018-2023(USD Million) Figure 98: Germany COPD Prevalence, 2013-2017, 2018E-20123E, (in Millions) Figure 99: PM2.5 air pollution, mean annual exposure (micrograms per cubic meter), 2012-2016 Figure 100: Germany, Population ages 65 and above, 2012-2017 (% total) Figure 101: Germany, Spending on Healthcare, 2015 & 2040E, (USD Per Person) Figure 102: Germany, Healthcare Related Statistics, 2017 Figure 103: Germany, Smoking Prevalence, Age 15+, 2012-2016, (% of Total) Figure 104: Germany, Percentage Change In Cause of Death Between 2007-2017 Figure 105: Germany COPD Drugs Market Size, By Drug Type, 2017 (%) Figure 106: Germany COPD Drugs Market Size, By Drug Type, 2023F (%) Figure 107: Germany COPD Drugs Market, By Drug Type, By Value, 2013-2017 (USD Million) Figure 108: France COPD Drugs Market, By Value, 2013-2017 (USD Million) Figure 109: France COPD Drugs Market, By Value, 2018-2023(USD Million) Figure 110: France, COPD Prevalence, 2013-2017, 2018E-20123E, (in Millions) Figure 111: France, Smoking Prevalence, Age 15+, 2012-2017, (% of Total) Figure 112: France, Healthcare Infrastructure Related Statistics Figure 113: France, PM2.5 air pollution, mean annual exposure (micrograms per cubic meter), 2017 Figure 114: France, Health Expenditure, (% of GDP), 2012-2015 (USD) Figure 115: France, Population Ages 65 and Above (% of total), 2012-2017 Figure 116: France, Cause of Death, 2017, (% of Total) Figure 117: France, Spending on Healthcare, 2015 & 2040, (USD Per Person) Figure 118: France COPD Drugs Market Size, By Drug Type, 2017 (%) Figure 119: France COPD Drugs Market Size, By Drug Type, 2023F (%) Figure 120: France COPD Drugs Market, By Drug Type, By Value, 2013-2017 (USD Million) Figure 121: U.K COPD Drugs Market, By Value, 2013-2017 (USD Million) Figure 122: U.K COPD Drugs Market, By Value, 2018-2023(USD Million) Figure 123: Germany, COPD Prevalence, 2013-2017, 2018E-20123E, (in Millions) Figure 124: U.K, Health Expenditure, (% of GDP), 2013-2017 (USD) Figure 125: U.K, Population Ages 65 and Above (% of total), 2012-2017 Figure 126: U.K, Population Ages 65 and Above (% of total), 2012-2017 Figure 127: U.K, Spending on Healthcare, 2015 & 2040, (USD Per Person) Figure 128: UK, PM2.5 air pollution, mean annual exposure (micrograms per cubic meter), 2012-2017 Figure 129: UK, Smoking Prevalence (% of Total), 2012-2017 Figure 130: U.K COPD Drugs Market Size, By Drug Type, 2017 (%) Figure 131: U.K COPD Drugs Market Size, By Drug Type, 2023F (%) Figure 132: U.K COPD Drugs Market, By Drug Type, By Value, 2013-2017 (USD Million) Figure 133: Italy COPD Drugs Market, By Value, 2013-2017 (USD Million) Figure 134: Italy COPD Drugs Market, By Value, 2018-2023(USD Million) Figure 135: Italy COPD Prevalence, 2013-2017, 2018E-2023E, (in Millions) Figure 136: Italy, Health Expenditure, (% of GDP), 2013-2017 (USD) Figure 137: Italy, Population Ages 65 and Above (% of total), 2012-2017 Figure 138: Italy, Healthcare Infrastructure Related Statistics Figure 139: Italy, Spending on Healthcare, 2015 & 2040, (USD Per Person) Figure 140: Italy, Smoking Prevalence, Age 15+, 2012-2016 Figure 141: Italy, PM2.5 air pollution, mean annual exposure (micrograms per cubic meter) 2012-2016 Figure 142: Italy COPD Drugs Market Size, By Drug Type, 2017 (%) Figure 143: Italy COPD Drugs Market Size, By Drug Type, 2023F (%) Figure 144: Italy COPD Drugs Market, By Drug Type, By Value, 2013-2017 (USD Million) Figure 145: APAC COPD Drugs Market, By Value, 2013-2017 (USD Million) Figure 146: GDP Per Capita in APAC, By Select Country, 2016 (In USD) Figure 147: Population ages 65 and above, By Select Country, 2017 (% of total) Figure 148: Men Smoking Prevalence in Asia, 2016, (% of Total Population) Figure 149: East Asia & Pacific, PM2.5 air pollution, mean annual exposure (micrograms per cubic meter), 2012-2016 Figure 150: South Asia, PM2.5 air pollution, mean annual exposure (micrograms per cubic meter), 2012-2016 Figure 151: China, Pharmaceuticals Industry Revenue (USD Billion) Figure 152: Japan, Total Drugs Market, 2013-2017, USD Billion Figure 153: India Pharma Market, 2015-2017, (USD Billion) Figure 154: APAC COPD Drugs Market, By Value, 2018-2023 (USD Million) Figure 155: APAC COPD Drugs Market Size, By Drug Type, 2017 (%) Figure 156: APAC COPD Drugs Market Size, By Drug Type, 2023F (%) Figure 157: APAC COPD Drugs Market, By Drug Type, By Value, 2013-2017 (USD Million) Figure 158: APAC COPD Drugs Market Size, By Countries, 2017 (%) Figure 159: APAC COPD Drugs Market Size, By Countries, 2023F (%) Figure 160: China COPD Drugs Market, By Value, 2013-2017 (USD Million) Figure 161: China COPD Drugs Market, By Value, 2018-2023(USD Million) Figure 162: China, Smoking Prevalence, Age 15+, % of Total Population, 2012-2016 Figure 163: China, Tobacco Attributable Deaths, 2030 Figure 164: China, PM2.5 air pollution, mean annual exposure (micrograms per cubic meter), 2012-2016 Figure 165: Beijing annual PM2.5 air pollution levels, 2013-2017, ( in micrograms per cubic meter of air) Figure 166: China Co2 Emissions, 2013-2016 (Billion Metric Tons) Figure 167: China, Population Above 65 (% of Total), 2013-2017 Figure 168: China, GDP Growth Per Year, 2015-2019 (In %) Figure 169: China, Share of Urban Population, 2012-2017 (In %) Figure 170: China, Total Population, 2013-2021F (In Billion) Figure 171: China COPD Drugs Market Size, By Drug Type, 2017 (%) Figure 172: China COPD Drugs Market Size, By Drug Type, 2023F (%) Figure 173: China COPD Drugs Market, By Drug Type, By Value, 2013-2017 (USD Million) Figure 174: Japan COPD Drugs Market, By Value, 2013-2017 (USD Million) Figure 175: Japan COPD Drugs Market, By Value, 2018-2023(USD Million) Figure 176: Japan, Population ages 65 and above, 2012-2017 (% of total) Figure 177: Japan, Smoking Prevalence, Age 15+, 2012-2016, (% of Total Prevalence) Figure 178: Japan, Medical Facilities Outlook Figure 179: Japan Healthcare Expenditure Outlook (%) Figure 180: Japan, PM2.5 air pollution, mean annual exposure (micrograms per cubic meter), 2012-2016 Figure 181: Japan, GDP Growth Per Year, 2015-2019F (In %) Figure 182: Japan COPD Drugs Market Size, By Drug Type, 2017 (%) Figure 183: Japan COPD Drugs Market Size, By Drug Type, 2023F (%) Figure 184: Japan COPD Drugs Market, By Drug Type, By Value, 2013-2017 (USD Million) Figure 185: India COPD Drugs Market, By Value, 2013-2017 (USD Million) Figure 186: India COPD Drugs Market, By Value, 2018-2023(USD Million) Figure 187: India, PM2.5 air pollution, mean annual exposure (micrograms per cubic meter), 2012-2017 Figure 188: India, Smoking Prevalence, Age 15+, 2012-2016, (% of Total) Figure 189: India, Diseases & Medical Industry Outlook Figure 190: India, Population ages 65 and above, 2013-2017 Figure 191: India, Total Population, 2013-2023F (In Billion) Figure 192: Pharma Export From India Market, 2013-2017, (USD Billion) Figure 193: India COPD Drugs Market Size, By Drug Type, 2017 (%) Figure 194: India COPD Drugs Market Size, By Drug Type, 2023F (%) Figure 195: India COPD Drugs Market, By Drug Type, By Value, 2013-2017 (USD Million) Figure 196: ROW COPD Drugs Market, By Value, 2013-2017 (USD Million) Figure 197: South Africa, PM2.5 air pollution, mean annual exposure (micrograms per cubic meter), 2013-2016 Figure 198: South Africa, PM2.5 air pollution, mean annual exposure (micrograms per cubic meter), 2013-2016 Figure 199: GDP Per Capita in ROW, By Select Country, 2013 (In USD) Figure 200: GDP Per Capita in ROW, By Select Country, 2013 (In USD) Figure 201: GDP Per Capita in ROW, By Select Country, 2013 (In USD) Figure 202: Middle East and North Africa, Population ages 65 and above (% of total) Figure 203: ROW COPD Drugs Market, By Value, 2018-2023 (USD Million) Figure 204: ROW COPD Drugs Market Size, By Drug Type, 2017 (%) Figure 205: ROW COPD Drugs Market Size, By Drug Type, 2023F (%) Figure 206: ROW COPD Drugs Market, By Drug Type, By Value, 2013-2017 (USD Million) Figure 207: Exacerbation During the Study Over a Period of 12 Months (Part B) Figure 208: Percentage aged 60 years and over, (2000, 2015, 2030,2050) Figure 209: COPD - Major Drugs Sales, By Drug Type, 2017 (USD Million) Figure 210: GSK COPD Drugs Sales, 2018-2023 Estimated, USD Million Figure 211: AstraZeneca COPD Drugs Sales, 2018-2023 Estimated, USD Million Figure 212: Novartis COPD Drugs Sales, 2018-2023 Estimated, USD Million Figure 213: COPD - Major Drugs Sales, By Drug Type, 2017 (USD Million) Figure 214: GSK, Revenues, 2013-2017 (USD Million) Figure 215: GSK, Revenues, 2013-2017 (USD Million) Figure 216: GSK, Revenue, By Segments, 2017(%) Figure 217: GSK, Revenue, By Pharmaceuticals Segment, 2017 (USD Million) Figure 218: GSK COPD Drugs Patent Expiry Details Figure 219: GSK, Respiratory Segment Expected Revenue By 2023 (USD Million) Figure 220: AstraZeneca, Net Sales, 2013-2017 (USD Million) Figure 221: AstraZeneca Revenue, By Segments, 2017(%) Figure 222: AstraZeneca Revenue, By Region, 2017(%) Figure 223: Boehringer-Ingelheim, Net Sales, 2013-2017 (USD Million) Figure 224: Boehringer-Ingelheim, By Segments, 2017(%) Figure 225: Boehringer-Ingelheim, By Region, 2017(%) Figure 226: Teva Pharmaceuticals, Net Sales, 2013-2017 (USD Million) Figure 227: Teva Pharmaceuticals, By Segments, 2017(%) Figure 228: Teva Pharmaceuticals, By Region, 2017(%) Figure 229: Chiesi Farmaceutici S.p.A. , Net Sales, 2013-2017 (USD Million) Figure 230: Chiesi Farmaceutici S.p.A. , By Segments, 2017(%) Figure 231: Chiesi Farmaceutici S.p.A. , By Segments, 2017(%) Figure 232: Novartis, Net Sales, 2013-2017 (USD Million) Figure 233: Novartis, Revenue, By Segment, 2017(%) Figure 234: Novartis, Revenue, By Region, 2017(%) Figure 235: Cipla, Net Sales, 2013-2017 (USD Million) Figure 236: Cipla , By Region, 2017(%) Figure 237: Mylan, Net Sales, 2013-2017 (USD Million) Figure 238: Mylan, By Region, 2017(%) Figure 239: Vectura Group , Net Sales, 2013-2017 (USD Million) Figure 240: Vectura Group, By Products, 2017(%) List of Tables Table A: Stages of COPD Table B: Beta-2 Agonist Drugs For in COPD Treatment Table C: Anti-muscarinic Drugs For COPD Treatment Table D: Combination Bronchodilators Therapy For COPD Treatment Table E: ICS Combination Therapy For COPD Treatment Table F: EU-5 Socio-Economical Statistics, 2017 Table G: PT010 Clinical Trails Table H: Other PT010 Phase-3 Trails Table I: Primary endpoint results assessed by FEV1 Table J: Duaklir Clinical Trails Table K: Statistical Analysis Table L: Statistical Analysis Table M: Statistical Analysis Table N: Statistical Analysis Table O: Statistical Analysis Table P: Statistical Analysis Table Q: Statistical Analysis Table R: Statistical Analysis Table S: Statistical Analysis Table T: Danirixin Clinical Studies Table U: Nemiralisib Clinical Studies Table V: GSK2269557 Clinical Studies Table W: Other Major Drugs In Development Pipeline Table X: Product Benchmarking, By Drug Type Table Y: GSK COPD Drugs Sales, 2017, USD Million Table Z: AstraZeneca COPD Drugs Sales, 2017, USD Million Table AB: Novartis COPD Drugs Sales, 2017, USD Million Table AC: Boehringer Ingelheim COPD Drugs Sales, 2017, USD Million Table AD: Product Benchmarking, By Drug Type

Name*
Email ID*
Company*
Phone (With Country Code)*
What is/are your question(s)?:

Other Reports by Azoth Analytics

Global Fluorochemical Market (Value, Volume): World Market Review By Product Type (Fluoro Carbon, Inorganic and Specialities), By Application, By End User Industry (2019 Edition): Opportunities and Forecast (2019-2024) - By Country (United States, Canada, France, Germany, Italy, Spain, India, China, Japan, South Korea)

Executive Summary The Global Fluorochemical Market was valued at USD 24,603.52 Million with Global production volume of 4,210 thousand tonnes during the year 2018. The reasons for the growth of Fluorochemical market is the thermal efficiency and che...

Global Acne Treatment Market: World Market Review By Product Type, Applications, By Region, By Country (2019 Edition): Opportunities and Forecast (2019-2024) ? By Country (USA, Canada, Germany, France, UK, Italy, Spain, China, India, Mexico)

Executive Summary Global Acne Market was valued at USD 5,124.98 Million in the year 2018. Increasing prevalence of acne occurs due to numerous factors such as fluctuating hormone level, unhealthy lifestyles, bad eating habits and excessive productio...

India Women Innerwear Market - Analysis By Product Type, By Price, By Distribution Channel (2019 Edition): Opportunities and Forecast (2019-2024)

Executive Summary The India Women Innerwear Market was valued at USD 2,900.97 Million in the year 2018. Women Innerwear Market is expected to grow due to a number of factors including rise in disposable income, increase in grooming awareness, rising...

Global Digital Oilfield Market - Analysis By Technology, End-Process, Application, By Region, By Country (2019 Edition): Opportunities and Forecast (2019-2024) - By Technology (Hardware, Software and Services, Data Storage Solutions), By End Process (Reservoir, Production and Drilling Optimization)

Executive Summary The Global Digital Oilfield Market was valued at USD 23,235.15 Million in the year 2018. Growing Exploration & Production (E&P) activities across the globe, exploration of shale resources as well as CAPEX improvement in upstream se...

Global Sports Nutrition Market (2019 Edition) - Analysis By Product Type (Powder, Sports Bars, Sports Drinks, Others), By Distribution Channel, By Region, By Country: Opportunities and Forecast (2019-2024)

Executive Summary The Sports Nutrition market was valued at USD 14,596.45 Million in the year 2018. Global Sports Nutrition market is expected to grow due to a number of factors including rapid urbanization in emerging economies, rising health conce...

New Pharmaceuticals and Healthcare Reports

Publisher: Azoth Analytics